Development of chimeric antigen receptor T cells targeting cancer-expressing podocalyxin

Area of Science:

• Immunotherapy
• Oncology
• Biotechnology

Background:

• Chimeric Antigen Receptor (CAR)-T cell therapy has transformed B-cell malignancy treatment.
• Podocalyxin (PODXL) is a transmembrane protein linked to cancer progression and poor prognosis.
• Existing CAR-T therapies face challenges in targeting solid tumors effectively and safely.

Purpose of the Study:

• To explore the potential of PODXL-targeted CAR-T cells using cancer-specific monoclonal antibody (CasMab) technology.
• To enhance the specificity and safety of CAR-T cell therapy for solid tumors.
• To evaluate the therapeutic efficacy and persistence of humanized CAR-T cells.

Main Methods:

• Developed CAR-T cells using single-chain variable fragments (scFvs) from cancer-specific (PcMab-6) and non-specific (PcMab-47) antibodies targeting PODXL.
• Conducted in vitro experiments to assess antitumor activity and off-target effects.
• Generated and tested humanized CAR-T cells for in vivo persistence and therapeutic efficacy.

Main Results:

• PcMab-6-derived CAR-T cells demonstrated significant in vitro antitumor activity.
• PcMab-6 CAR-T cells exhibited reduced off-target effects on normal cells compared to PcMab-47 controls.
• Humanized PcMab-6 CAR-T cells showed extended antitumor effects in vivo, indicating enhanced persistence.

Conclusions:

• CasMab technology enables the generation of highly specific and safer CAR-T cell therapies for solid tumors.
• Humanized PODXL-targeted CAR-T cells hold promise for prolonged therapeutic activity and clinical application.
• This approach represents a significant advancement in CAR-T cell therapy for challenging cancers.